We are live on ! Find out more
IOVA icon

Iovance Biotherapeutics
IOVA

252 hedge funds and large institutions have $4.58B invested in Iovance Biotherapeutics in 2020 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 83 increasing their positions, 91 reducing their positions, and 51 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% more call options, than puts

Call options by funds: $52.7M | Put options by funds: $26.5M

18% more capital invested

Capital invested by funds: $3.88B → $4.58B (+$704M)

0% more funds holding in top 10

Funds holding in top 10: 9 → 9 (0)

0.67% less ownership

Funds ownership: 96.25% → 95.58% (-0.67%)

9% less repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 91

10% less first-time investments, than exits

New positions opened: 46 | Existing positions closed: 51

2% less funds holding

Funds holding: 257 → 252 (-5)

Holders
252
Holders Change
-5
Holders Change %
-1.95%
% of All Funds
5.08%
Holding in Top 10
9
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.18%
New
46
Increased
83
Reduced
91
Closed
51
Calls
$52.7M
Puts
$26.5M
Net Calls
+$26.2M
Net Calls Change
-$19.2M

Top Buyers

1
AIM
ARK Investment Management
Florida
+$112M
2
Franklin Resources
Franklin Resources
California
+$41.6M
3
NAMA
Nikko Asset Management Americas
New York
+$23.5M
4
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group
Japan
+$23.3M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$13.4M

Top Sellers

1
PA
Perceptive Advisors
New York
-$52.8M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$30M
3
ACA
Avoro Capital Advisors
New York
-$25.3M
4
EAM
Eagle Asset Management
Florida
-$19.8M
5
Goldman Sachs
Goldman Sachs
New York
-$18.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
ACI
276
AMP Capital Investors
Australia
– -$269K -9,900 Closed
JG
277
Jefferies Group
New York
– -$268 -9,757 Closed
SEC
278
Seven Eight Capital
New York
– -$258K -9,397 Closed
EWM
279
Edge Wealth Management
New York
– -$251K -9,144 Closed
PM
280
Parametrica Management
Hong Kong
– -$240K -8,754 Closed
NIT
281
NumerixS Investment Technologies
British Columbia, Canada
– -$217K -7,900 Closed
FRM
282
Fox Run Management
Connecticut
– -$211K -7,670 Closed
APWM
283
Atlas Private Wealth Management
New York
– -$165K -6,000 Closed
PAG
284
Private Advisor Group
New Jersey
– -$122K -4,452 Closed
OCM
285
Ovata Capital Management
Hong Kong
– -$119K -4,320 Closed
SGAM
286
Smith Group Asset Management
Texas
– -$114K -4,150 Closed
PHK
287
Point72 Hong Kong
Hong Kong
– -$110K -3,996 Closed
CAN
288
Cetera Advisor Networks
California
– -$96K -3,500 Closed
QI
289
QS Investors
New York
– -$80K -2,900 Closed
RDWM
290
Red Door Wealth Management
Tennessee
– -$41K -1,500 Closed
CFG
291
Citizens Financial Group
Rhode Island
– -$27K -1,000 Closed
LC
292
Lindbrook Capital
California
– -$27K -1,000 Closed
RCA
293
Ranch Capital Advisors
Florida
– -$28K -1,000 Closed
HFA
294
Hoover Financial Advisors
Pennsylvania
– -$21K -750 Closed
ACA
295
Atlas Capital Advisors
Wyoming
– -$17.8K -650 Closed
AWM
296
Apollon Wealth Management
South Carolina
– -$14K -500 Closed
KPW
297
Kore Private Wealth
New York
– -$13K -500 Closed
VFA
298
Valeo Financial Advisors
Indiana
– -$5K -175 Closed
QT
299
Quantbot Technologies
New York
– -$2K -74 Closed
S
300
SignatureFD
Georgia
– -$1K -49 Closed
9 10 11
12
13

IOVA Hedge Fund Activity: Q3 2020 in Review

252 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q3 2020, worth a combined $4.58B — up 18% from $3.88B a quarter earlier.

Sellers outnumbered buyers: 51 funds closed out of IOVA and 46 opened new positions — a net loss of 5 holders — while 91 trimmed existing stakes and 83 added.

The largest buyer was ARK Investment Management, adding an estimated $112M. The largest seller was Perceptive Advisors, cutting an estimated $52.8M.

  • 252 institutional investors held Iovance Biotherapeutics (IOVA) as of Q3 2020, down from 257 in Q2 2020.
  • Funds reported $4.58B of Iovance Biotherapeutics stock for Q3 2020, up 18% quarter-over-quarter.
  • 46 funds opened new Iovance Biotherapeutics positions in Q3 2020 and 51 closed out, a net change of -5 holders.
  • The largest Iovance Biotherapeutics buyer in Q3 2020 was ARK Investment Management, an estimated $112M added.
  • The largest Iovance Biotherapeutics seller in Q3 2020 was Perceptive Advisors, an estimated $52.8M sold.

Based on aggregated 13F filings for Q3 2020.